CareDx Inc. Common Stock (CDNA)
Stock · NASDAQ · Health Care
$64.02as of 10/16/2026
Price chart
Active signals
CDNA Signal Track Record
How signals performed across all stocks →What CDNA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -0.4% | 47% | October 6, 2026 |
| Bollinger Band Breakout | 28 | +4.6% | 61% | September 17, 2026 |
| Bollinger Band Breakdown | 21 | +5.9% | 57% | April 10, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +21.0% | 86% | April 13, 2026 |
| Any 20-session window (baseline) | +0.8% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CDNA
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; an…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 761
- Website
- www.caredx.com/
Fundamentals
- 1-day range
- $62.21$67.55
- Market cap
- $2.32B
- P/E (trailing)
- 30.15
- P/E (forward)
- 51.91
- EPS (trailing)
- $2.07
- Dividend yield
- —
- Beta
- 2.58
- Avg. volume
- 1.32M
How CareDx Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
CareDx Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CDNACareDx Inc. Common Stock$64▼ 4.01%Market cap $2.32BP/E 30.15$14.03$72.51
- CLOVClover Health Investments Corp. Class A Common Stock$4.48▼ 4.27%Market cap $2.45BP/E —$1.58$5.59
- GRALGRAIL Inc. Common Stock$117.81▼ 13.03%Market cap $2.72BP/E —$41.5$166.48
- ALHCAlignment Healthcare Inc. Common Stock$8.28▲ 1.60%Market cap $2.78BP/E 41.54$6.01$25.12
- ACHCAcadia Healthcare Company Inc. Common Stock$29.98▼ 3.41%Market cap $2.86BP/E —$11.43$35.83
- FTREFortrea Holdings Inc. Common Stock$22.49▼ 1.12%Market cap $1.68BP/E —$8.55$23.51
- PSNLPersonalis Inc. Common Stock$15.65▼ 1.76%Market cap $1.39BP/E —$4.96$18.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CDNA CareDx Inc. Common Stock | $2.32B | 30.15 | $64 | ▼ 4.01% | $14.03$72.51 |
| CLOV Clover Health Investments Corp. Class A Common Stock | $2.45B | — | $4.48 | ▼ 4.27% | $1.58$5.59 |
| GRAL GRAIL Inc. Common Stock | $2.72B | — | $117.81 | ▼ 13.03% | $41.5$166.48 |
| ALHC Alignment Healthcare Inc. Common Stock | $2.78B | 41.54 | $8.28 | ▲ 1.60% | $6.01$25.12 |
| ACHC Acadia Healthcare Company Inc. Common Stock | $2.86B | — | $29.98 | ▼ 3.41% | $11.43$35.83 |
| FTRE Fortrea Holdings Inc. Common Stock | $1.68B | — | $22.49 | ▼ 1.12% | $8.55$23.51 |
| PSNL Personalis Inc. Common Stock | $1.39B | — | $15.65 | ▼ 1.76% | $4.96$18.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CareDx (CDNA) Stock Gets Fair Value Bump After Reimbursement And Analyst Target ChangesYahoo · 10/10/2026
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha · 10/7/2026
- Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile UpBenzinga · 10/6/2026
- Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 PicksYahoo · 9/30/2026
- CareDx: I Was Wrong, But The Rally Has Outrun The Fundamentals (Rating Upgrade)SeekingAlpha · 9/25/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 9/25/2026
- CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?Yahoo · 9/25/2026
- CareDx +14% on Fresh $74 Analyst Price TargetYahoo · 9/24/2026
Insider Activity
Insider Actions →- Goldberg Michael · October 2, 2026 · Grant588
- Meng Jessica · October 1, 2026 · Tax Withholding2.6K @ $66.23
- Novack Jeffrey Adam · October 1, 2026 · Tax Withholding997 @ $66.23
- Hanna John Walter JR · October 1, 2026 · Tax Withholding8.5K @ $66.23
- Kennedy Keith · October 1, 2026 · Tax Withholding3.0K @ $66.23
- Meng Jessica · September 12, 2026 · Tax Withholding6.7K @ $52.37
- Kennedy Keith · September 12, 2026 · Tax Withholding8.2K @ $52.37
- Novack Jeffrey Adam · August 5, 2026 · Sale500 @ $46.75
- Novack Jeffrey Adam · August 5, 2026 · Sale2.2K @ $46.15
- Bickerstaff George · August 5, 2026 · Sale20.0K @ $46.29
- Goldberg Michael · August 4, 2026 · Sale44.7K @ $47.06
- Christine Cournoyer · August 4, 2026 · Sale16.0K @ $46.94
- Novack Jeffrey Adam · August 1, 2026 · Tax Withholding2.9K @ $47.85
- Hannah Valantine · July 16, 2026 · Option Exercise5.1K @ $7.96
- Hannah Valantine · July 16, 2026 · Option Exercise16.0K @ $14.19
Institutional Ownership
March 31, 2026
- Total shares held
- 51.24M
- Total value held
- $882.97M
- Institutional holders
- 184
- Unknown4.52M
- Unknown3.34M
- Unknown2.76M
- Unknown2.23M
- Unknown2.19M
- Unknown2.17M
- Unknown2.16M
- Unknown1.88M
- Unknown1.76M
- Unknown1.50M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
CareDx shows high growth and fair‑value boost after reimbursement news
Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.
CareDx shows high growth and fair‑value boost after reimbursement news. Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.